Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction ...

Regeneron’s strategy relies on two experimental lab-made antibodies, trevogrumab and garetosmab. Both antibodies are linked to separate proteins that play key roles in limiting skeletal muscle ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth.

Regeneron has promising muscle preservation in obesity treatment, "Trevogrumab," in phase two. Libtayo is Regeneron's PD-1 inhibitor approved for certain skin cancers and is under investigation ...